Holen Sie sich die Stockscreener-App
1.24
0.80%
-0.01
Schlusskurs vom Vortag:
$1.25
Offen:
$1.25
24-Stunden-Volumen:
502.31K
Relative Volume:
0.25
Marktkapitalisierung:
$120.96M
Einnahmen:
$1.20M
Nettoeinkommen (Verlust:
$-52.41M
KGV:
-1.3626
EPS:
-0.91
Netto-Cashflow:
$-31.25M
1W Leistung:
+1.64%
1M Leistung:
-12.68%
6M Leistung:
+134.85%
1J Leistung:
-32.61%
1-Tages-Spanne:
$1.23
$1.295
1-Wochen-Bereich:
$1.17
$1.415
52-Wochen-Spanne:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Firmenname
Rani Therapeutics Holdings Inc
Sektor
Branche
Telefon
(408) 457-3700
Adresse
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
1.24 | 121.94M | 1.20M | -52.41M | -31.25M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-14 | Eingeleitet | Maxim Group | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-07-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Rani Therapeutics Holdings Inc Aktie (RANI) Neueste Nachrichten
Does Rani Therapeutics Holdings Inc. offer margin of safety2025 Year in Review & Safe Investment Capital Preservation Plans - mfd.ru
Published on: 2026-02-13 18:32:35 - baoquankhu1.vn
Can Rani Therapeutics Holdings Inc. reach all time highs this yearQuarterly Earnings Summary & AI Driven Price Predictions - mfd.ru
Is Rani Therapeutics Holdings Inc. stock near bottom after decline2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Rani Therapeutics Holdings Inc. (RANI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Income Plays: What is the next catalyst for Rani Therapeutics Holdings IncWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Published on: 2026-02-02 11:44:32 - baoquankhu1.vn
What is the next catalyst for Rani Therapeutics Holdings IncWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Insider Buyers At Rani Therapeutics Holdings Sitting On US$1.3m Profit - simplywall.st
Rani Therapeutics promotes Alireza Javadi to chief technical officer By Investing.com - Investing.com South Africa
Rani Therapeutics Holdings, Inc. Announces Promotion of Alireza Javadi to Chief Technical Officer - marketscreener.com
Rani Therapeutics announces the promotion of Alireza Javadi, Ph.D. to chief technical officer - marketscreener.com
Rani Therapeutics Names Alireza Javadi Chief Technical Officer - Nasdaq
Rani Therapeutics promotes Alireza Javadi to chief technical officer - Investing.com
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer - The Manila Times
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bear Alert: Does CompoSecure Inc Equity Warrant stock have upside surprise potential2025 Sector Review & Daily Stock Trend Watchlist - baoquankhu1.vn
Published on: 2026-01-24 03:15:13 - baoquankhu1.vn
AI Stocks: Does XBiotech Inc offer margin of safety2025 Macro Impact & Short-Term High Return Ideas - baoquankhu1.vn
Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17% - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY) - The Globe and Mail
Rani Therapeutics finalizes governance and capital structure changes - MSN
Targets Report: Can Rani Therapeutics Holdings Inc navigate macro headwindsJuly 2025 Chart Watch & Consistent Return Investment Signals - baoquankhu1.vn
Price Action: Can Rani Therapeutics Holdings Inc navigate macro headwinds2025 Technical Patterns & Community Supported Trade Ideas - baoquankhu1.vn
HOKA Shoe Comparison: Will Rani Therapeutics Holdings Inc. stock outperform tech sector in 2025Grip and Outsole Review & quick comparison of popular models - Улправда
HC Wainwright Reaffirms Buy Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
RANI: HC Wainwright Reiterates Buy Rating with $11 Target | RANI Stock News - GuruFocus
Is Rani Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Summary & Consistent Return Investment Signals - Улправда
How Rani Therapeutics Holdings Inc. stock reacts to inflationary pressuresTrade Risk Report & Long-Term Investment Growth Plans - Улправда
How Rani Therapeutics Holdings Inc. stock compares to growth peersJuly 2025 Chart Watch & Verified Momentum Stock Watchlist - Улправда
Can Rani Therapeutics Holdings Inc. stock sustain revenue growthQuarterly Profit Report & Verified Momentum Stock Alerts - Улправда
Can Rani Therapeutics Holdings Inc. stock hit record highs againQuarterly Profit Review & Growth Focused Entry Point Reports - Улправда
Aug Intraday: Is Rani Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Volume & Scalable Portfolio Growth Methods - Улправда
Rani Therapeutics begins phase 1 trial of oral obesity treatment By Investing.com - Investing.com Australia
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen - The Manila Times
Rani Therapeutics begins phase 1 trial of oral obesity treatment - Investing.com
Rani Therapeutics Initiates Phase 1 Study of RT-114 - GlobeNewswire
Can Rani Therapeutics Holdings Inc. stock rebound after recent weaknessMorning Star Patterns & Invest Now - Улправда
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Rani Therapeutics amends charter, reduces Class B voting power and ends tax agreement - Investing.com Nigeria
Finanzdaten der Rani Therapeutics Holdings Inc-Aktie (RANI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rani Therapeutics Holdings Inc-Aktie (RANI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):